Deciphera Pharmaceuticals Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Deciphera Pharmaceuticals's estimated annual revenue is currently $12.9M per year.
- Deciphera Pharmaceuticals received $128.0M in venture funding in October 2017.
- Deciphera Pharmaceuticals's estimated revenue per employee is $41,902
- Deciphera Pharmaceuticals's total funding is $270.4M.
- Deciphera Pharmaceuticals has 307 Employees.
- Deciphera Pharmaceuticals grew their employee count by 134% last year.
- Deciphera Pharmaceuticals currently has 20 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Vita Data Scien...||$8.4M||42||50%||N/A|
What Is Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the effectiveness of many cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a 'switched off or inactivated conformation. Deciphera has developed a diverse pipeline of drug candidates designed to improve outcomes for patients with cancer by enhancing the quality, rate and/or durability of their responses to treatment.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Daniel Flynn||evp/Founder & Chief Scientific Officer|
|Adam Branvold||Sr. Director Global Field Medical Excellence|
|Mike Kaufman||Vice President Chemistry And Preclinical Development|
|Julie Todd||Associate Director Marketing Operations|
|Joe Li||Director of Biostatistics|
|Chelsea Mencio||Senior Manager, Medical Affairs|
|Irene Callender||Associate Director, IT||Email Available|
|Simin Hu||Associate Director||Email Available|
|Kristin Tzetzo||Sr Human Resources Business Partner|
|Heather Vital||Senior Director, Program Leadership|
Deciphera Pharmaceuticals News
Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation of Pivotal Phase 3 INVICTUS Data at the European Society for ...
Shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) erupted for gains of over 115% today after the clinical-stage pharma reported ...
BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing ...
Deciphera Pharmaceuticals Funding
|2003-12-24||$15.0M||Lead Investor: Undis||Article|
|2015-09-22||$75.0M||B||New Leaf Venture Partners||Article|
|2016-01-06||$90.0M||B||New Leaf Venture Partners||Article|
|2017-06-05||$52.0M||Undisclosed||Viking Global Investors LP||Article|
Deciphera Pharmaceuticals Executive Hires
|2014-04-08||Michael D. Taylor||President/CEO||Article|
|2014-07-01||Oliver Rosen||Chief Medical Officer||Article|
|2016-10-07||Christopher J. Morl||Chief Business Officer||Article|
|2018-09-19||Daniel Martin||Chief Commercial Officer||Article|
Deciphera Pharmaceuticals New Location/Offices